Timeline

FinnGen study is a 10-year project that started in August 2017 and is divided into two phases, FinnGen 1 (years 1-3) and FinnGen 2 (years 4-6). During these six years, the biobank samples are collected and genotyped. FinnGen produces new datasets every 6 months.

FinnGen is a growing project, aiming at 500,000 individuals in 2023. The table below shows the release schedule and sample sizes of the past and upcoming data freezes:

FinnGen data freezes
Release number	Released to partners	Sample size (genotype + phenotype data)	Public release (results)
DF1	Feb 2018	51,959
DF2	Aug 2018	96,499	Q1 2020
DF3	Feb 2019	135,638	Q2 2020
DF4	Aug 2019	176,899	Q4 2020
DF5	Feb 2020	218,792	Q2 2021
DF6	Aug 2020	269,077	Q1 2022
DF7	Feb 2021	321,302
DF8	Aug 2021	356,077
DF9	Feb 2022	~392,000
DF10	Aug 2022	~410,000
DF11	Feb 2023	~445,000
DF12	Aug 2023	~480,000
DF13	Feb 2024	~500,000

FinnGen in brief

FinnGen is a large public-private partnership aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.